Eli Lilly and Company (FRA:LLY)
Germany
· Delayed Price · Currency is EUR 674.80
+5.30 (0.79%)
At close: Jun 6, 2025, 10:00 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Glucagon | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Glucagon Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Humalog | 2.32B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Humalog Growth | 33.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Humulin | 884.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Humulin Growth | 9.66% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Trajenta | 341.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Trajenta Growth | -12.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology | 8.89B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Growth | 24.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience | 1.36B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuroscience Growth | -53.34% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product | 873.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Growth | -19.74% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Jardiance | 3.67B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Jardiance Growth | 28.56% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Trulicity | 4.89B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Trulicity Growth | -26.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Basaglar | 692.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Basaglar Growth | 2.41% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Cardiometabolic Health | 137.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Cardiometabolic Health Growth | -8.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immunology | 4.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immunology Growth | 20.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Baqsimi | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Baqsimi Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Mounjaro | 13.58B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Mounjaro Growth | 112.08% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Zepbound | 6.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Zepbound Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| US Revenue | 33.17B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Revenue Growth | 43.91% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 7.87B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | 20.60% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan | 1.85B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan Growth | 12.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Foreign Countries | 4.38B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Foreign Countries Growth | 38.21% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | 1.74B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | 12.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Revenue Change due to Price | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Revenue Change due to Price Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Revenue Change due to Volume | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Revenue Change due to Volume Growth | 64.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Revenue Change due to FX | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Revenue Change due to FX Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|